Crinecerfont clinical trials
Crinecerfont is named as an intervention in 4 current clinical trials in our USA, Germany, UK, France, Spain, Italy, Belgium, Poland, Canada, Netherlands, Sweden, Austria, Czechia, Portugal and Israel registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Neurocrine Biosciences (2). The most-studied condition is Congenital Adrenal Hyperplasia. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Crinecerfont is approved
All regulators →Of the three regulators tracked here, the first to approve Crinecerfont was the US, on 13 Dec 2024.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Crinecerfont patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Crinecerfont, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 5 listed patents; the last listed expires 12 Jan 2043 (US 12582634).
- Latest patent on the drug substance itself: 12 Jan 2043 (US 12582634).
- Exclusivity ODE-503: Orphan drug exclusivity: adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years o…, until 13 Dec 2031.
- Exclusivity NCE: New chemical entity, until 13 Dec 2029.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Crinecerfont works
All drug targets →- Corticotropin releasing factor receptor 1 antagonist AntagonistTarget: CRHR1 corticotropin releasing hormone receptor 1✓ In ChEMBL and the Guide to Pharmacology
- Anxiety disorderPhase 2
- Major depressive disorderPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL291657, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 3533, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Crinecerfont
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Crinecerfont
- ChEMBL
- CHEMBL291657
- DrugBank
- DB18518
- PubChem CID
- 5282340
- CAS number
- 752253-39-7
- FDA UNII
- MFT24BX55I
- Wikidata
- Q27088874
- Wikipedia
- Crinecerfont
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Crinecerfont
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Crinecerfont in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Crinecerfont. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
2025-524282-24-00 · Hormonal diseases
|
Phase 3 | Authorised | Neurocrine Biosciences Inc | Czechia, Germany, Sweden + 6 more |
Crinecerfont across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Supply shortages
- Crinecerfont CapsuleUS (FDA) · Resolved · updated 28 Apr 2026
Conditions studied with Crinecerfont
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Neurocrine Biosciences | 2 |
| Neurocrine Switzerland GmbH | 2 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Crinecerfont trials
How many clinical trials are testing Crinecerfont?
4 current trials in our USA, Germany, UK, France, Spain, Italy, Belgium, Poland, Canada, Netherlands, Sweden, Austria, Czechia, Portugal and Israel registers name Crinecerfont (also registered as NBI-74788) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Crinecerfont trials recruiting patients?
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Crinecerfont clinical trials?
Neurocrine Biosciences (2) and Neurocrine Switzerland GmbH (2). The number in brackets is how many trials each organisation leads.
Is there a Crinecerfont shortage?
The registers we track list 1 entry for Crinecerfont: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Crinecerfont works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Crinecerfont works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Crinecerfont (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.